טריטייס 2.5 מג
sanofi israel ltd - ramipril - טבליה - ramipril 2.5 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.
טריטייס 5 מג
sanofi israel ltd - ramipril - טבליה - ramipril 5 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.
זאלטראפ
sanofi - aventis israel ltd - aflibercept 25 mg/ml - concentrate for solution for infusion - zaltrap, in combination with 5-fluorouracil, leucovorin, irinotecan (folfiri), is indicated for adults with metastatic colorectal cancer (mcrc) that is resistant to or has progressed following an oxaliplatin-containing regimen.
אובג'יו
sanofi israel ltd - teriflunomide - טבליות מצופות פילם - teriflunomide 14 mg - teriflunomide
דפלפט כרונו 500 מג
sanofi - aventis israel ltd - valproic acid; valproic acid as sodium - טבליות בשחרור ממושך - valproic acid 145 mg; valproic acid as sodium 333 mg - valproic acid
דפלפט כרונו 500 מג
sanofi israel ltd - valproic acid; valproic acid as sodium - טבליות בשחרור ממושך - valproic acid 145 mg; valproic acid as sodium 333 mg - valproic acid
טוג'או
sanofi israel ltd - insulin glargine - תמיסה להזרקה - insulin glargine 300 u/ml - insulin glargine
ליקסומיה 10 מקג
sanofi - aventis israel ltd - lixisenatide - תמיסה להזרקה - lixisenatide 10 mcg / 0.2 ml - lixisenatide
ליקסומיה 20 מקג
sanofi - aventis israel ltd - lixisenatide - תמיסה להזרקה - lixisenatide 20 mcg / 0.2 ml - lixisenatide
סוליקווה 33100
sanofi israel ltd - insulin glargine; lixisenatide - תמיסה להזרקה - lixisenatide 33 mcg / 1 ml; insulin glargine 100 units / 1 ml - insulin glargine